KMPH KEMPHARM INC

Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026

Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026

CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has been invited to ring the Nasdaq opening bell on Monday, February 9, 2026. Neil F. McFarlane, Zevra's President and Chief Executive Officer, will deliver opening remarks at 9:24 a.m. followed by the bell ringing at 9:30 a.m. ET, signifying the start of the day's trading session.

The opening bell ceremony can be seen live at and on the Nasdaq MarketSite Tower at 43rd and Broadway in New York, NY.

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a purpose-driven, commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases. The company’s commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disorder, provides a strong corporate foundation and validates its ability to advance therapies. In addition, the company is broadening access through geographic expansion opportunities and has a pipeline of rare disease programs. Zevra is a patient-centric organization guided by our values of accountability, integrity, innovation and courage, with the goal of creating long-term value for patients, partners, and shareholders.

For more information, please visit or follow us on and .

Investor Contact

Nichol Ochsner 

+1 (732) 754-2545 

  

Media Contact

Julie Downs

+1 (508) 246-3230



EN
02/02/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on KEMPHARM INC

 PRESS RELEASE

Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday,...

Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has been invited to ring the Nasdaq opening bell on Monday, February 9, 2026. Neil F. McFarlane, Zevra's President and Chief Executive Officer, will deliver opening remarks at 9:24 a.m. followed by the bell ringing at 9:30 a.m. ET, signifying the start of the day's tr...

 PRESS RELEASE

Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22...

Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™ Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings, MD Company to host satellite symposium on diagnostic and therapeutic advances in Niemann-Pick disease type C (NPC) CELEBRATION, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today...

 PRESS RELEASE

Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcar...

Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference CELEBRATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, CA on Thursday, January 15, 2026, at 9:45 a.m. PT. Additionally, management will be available for one-on-one meetings with registered conference a...

 PRESS RELEASE

Zevra Therapeutics Executes Distribution Agreement to Broaden Access t...

Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC) CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has executed an exclusive expanded access distribution agreement with Uniphar, an Ireland-based pharmaceutical services provider with a proven record of success in global warehousing, distribution and supply ch...

 PRESS RELEASE

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Ru...

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 53,000 shares of the Company’s common stock (the “Inducement Awards”) to three new employees pursuant to the Company’s 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”)....

ResearchPool Subscriptions

Get the most out of your insights

Get in touch